Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2005

View Archived Issues

SCP-123: a novel intravenous analgesic

Antihyperalgesic and antidepressant effects of novel delta opioid receptor agonists

KJ-0530 shows antiinflammatory response following cerebral ischemic insult

GlaxoSmithKline: Q3 report

New Zealand scientists develop a novel hypoxic cytotoxin for tumor therapy

NCI reports on the discovery of a dual topoisomerase I/II inhibitor

Advisory Committee speaks on licensure of pneumococcal conjugate vaccines

FDA Advisory Committee recommends more data for Certican approval

Phase IIa study begins for MEM-1003 in Alzheimer's disease

StaphVAX fails to meet primary endpoint in phase III study

Novacea plans new phase III study of DN-101 in prostate cancer

Oncophage studied in phase I/II trial for glioma

Pfizer and Incyte collaborate on novel oral CCR2 antagonists

In vitro studies suggest utility of Multiferon against H5N1 avian flu virus

PRECISE trial reaches criterion for second futility statistical analysis

Merck KGaA acquires Survac

Notice of noncompliance for Marqibo in Canada

GSK-248451 classified as a potent, competitive and selective UT antagonist

Indian scientists present in vitro and in vivo data on a novel antiarthritic compound, P-979

CH-1504 shows advantages over methotrexate in advanced rheumatoid arthritis

RN-624 reduces pain due to knee osteoarthritis

AME-527 shows promise in rheumatoid arthritis patients

PEG-Uricase lowers plasma urate levels, may resolve tophi in gout patients

ATTAIN, AIM, ASSURE study data detail abatacept efficacy in rheumatoid arthritis

New treatments for cancer covered in recent patents

Novel antibacterial compounds from Prolysis

Recent patents report new therapeutic agents for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...